Skåne University Hospital provides innovative and comprehensive diagnostics and treatment of cancer for all ages, as well as hematologic and immunologic diseases.
Our integrated teams deliver unique medical results for HSCT patients with:
- Malignant disease such as acute leukemia and solid tumors
- Non-malignant diseases such as immune-deficiency, thalassemia, osteopetrosis, sickle cell anemia, and mucopolysaccharidosis.
We are one of the few centres in Europe to regularly perform haploidentical SCT which is performed when an identical donor cannot be found.
Skåne University Hospital have achieved successful results where other treatment protocols have failed.
We also perform allogeneic SCT, which involves tissue typing based on the patient’s human leukocyte antigens (HLA).
Donors can be siblings or matched unrelated donors. Tissue typing is also performed to identify malignant and non-malignant diseases.
A World Leader in Research
Skåne University Hospital works closely with the medical faculty at Lund University, one of the top 100 universities in the world. Lund Stem Cell Center (SCC) is a global leader in STC exploration. With 35 research groups, all performing fundamental, multidisciplinary analyses, predominantly within the fields of neurology and hematology. It develops innovative ways to treat neurological diseases, blood disorders, cancer and diabetes, among others. Facilities include: bioinformatics, electrophysiology, embryonic (ES) cells and induced pluripotent stem (iPS), FACS, imaging and vector.
SCT patients from Iceland are treated at Skåne University Hospital, thanks to Skåne Cares’ partnership with Icelandic Health Insurance (Sjúkratryggingar Íslands). This collaboration also provides the country with access to invaluable knowledge. Which enables the advancement of treatment in Iceland in the future.
To access world-class knowledge, contact us.